HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

Interleukin-6 (Interleukin 6)

Subscribe to New Research on Interleukin-6

A cytokine that stimulates the growth and differentiation of B-LYMPHOCYTES and is also a growth factor for HYBRIDOMAS and plasmacytomas. It is produced by many different cells including T-LYMPHOCYTES; MONOCYTES; and FIBROBLASTS.

Also Known As:

Interleukin 6; IL6; B Cell Stimulatory Factor-2; B-Cell Differentiation Factor; B-Cell Differentiation Factor-2; B-Cell Stimulatory Factor 2; B-Cell Stimulatory Factor-2; BSF-2; Differentiation Factor, B-Cell; Differentiation Factor-2, B-Cell; IFN-beta 2; B Cell Differentiation Factor; B Cell Differentiation Factor 2; B Cell Stimulatory Factor 2; Differentiation Factor 2, B Cell; Differentiation Factor, B Cell; Differentiation-Inducing Protein, Myeloid; Growth Factor, Hybridoma; Growth Factor, Plasmacytoma; Hepatocyte Stimulating Factor; Myeloid Differentiation Inducing Protein; Hepatocyte-Stimulating Factor; Hybridoma Growth Factor; IL-6; MGI-2; Myeloid Differentiation-Inducing Protein; Plasmacytoma Growth Factor

Networked: 28211 relevant articles (732 outcomes, 3500 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Rose-John, Stefan: 95 articles (10/2015 - 05/2002)
2.	Nishimoto, Norihiro: 52 articles (03/2015 - 01/2002)
3.	Kishimoto, Tadamitsu: 41 articles (05/2015 - 01/2002)
4.	Chaudry, Irshad H: 41 articles (05/2015 - 01/2002)
5.	Scheller, Jürgen: 40 articles (07/2015 - 05/2005)
6.	Choudhry, Mashkoor A: 30 articles (10/2014 - 11/2004)
7.	Schwacha, Martin G: 29 articles (08/2014 - 01/2002)
8.	Culig, Zoran: 28 articles (02/2016 - 07/2002)
9.	Ferrucci, Luigi: 27 articles (10/2015 - 03/2003)
10.	Zhang, Wei: 26 articles (10/2015 - 11/2002)

Related Diseases

1.	Inflammation 11/19/1999 - "The bioactivity of interleukin-6 (IL-6) was found to be dramatically reduced in fluids from sites of inflammation. " 06/01/2007 - "Increased vascular inflammation, including enhanced expression of interleukin- 6 (IL-6), vascular cellular adhesion molecule-1 (VCAM-1) and monocyte chemoattractant protein (MCP- 1) are observed, as is a marked decrease in NO bioavailability. " 03/01/2012 - "The inflammation and oxidative stress parameters IL-6, TNF-α, CRP, and ROS decreased significantly in arm 1, while no significant change was observed in arm 2. The combined treatment improved both immunometabolic alterations and patient QoL. " 01/01/2010 - "There was significantly greater IL-6 immunoreactivity in biopsies with confirmed histologic inflammation (p = 0.004). " 08/01/2009 - "All responses were induced rapidly, independently of signals from other cells, and closely mimicked the pro-inflammatory and protective effects of inflammation modulators LPS in KC and IL-6 in HC. "
2.	Neoplasms (Cancer) 05/01/1994 - "In cancer patients, increased IL-6 serum levels were related to the presence of the tumor since all post-operative patients exhibited a marked decrease. " 01/01/2015 - "A significant reduction in SCF values and a significant increase in OPG and IL-6 values were also observed within cancer cell-positive peritoneal fluid. " 06/01/2010 - "While the in vitro proliferation rates of both transfectants and the parental line were similar, high expression of IL-6 induced a significant reduction in tumor growth in vivo. " 11/01/2007 - "Therapeutic targeting of IL-6 and its receptor in cancer has strong biologic rationale, and there is preliminary evidence suggesting that targeting of the IL-6 system may be beneficial in the treatment of cancer." 08/01/2005 - "Thus, therapeutic strategies aimed at inhibiting the production, expression or action of IL-6 would be quite beneficial in the treatment of cancer. "
3.	Infection 01/01/2014 - "For IL-6 -572 C/G, the controls with spontaneous clearance of HBV have significantly higher allele G (0.302 vs. 0.21, p = 0.002) and GG genotype frequency (0.075 vs. 0.032, p = 0.006) compared to the chronic HBV infection patients. " 06/01/2011 - "Serum levels of interleukin-6 and nuclear factor κB (NF-κB) activation in spleen cells were remarkably reduced in fnbA or fnbA fnbB mutant infections; however, there was no significant reduction in fnbB mutant infections. " 01/01/2011 - "JEV infection induced neuronal expression of IL-6, IL-12p70, MCP-1, IP-10 and TNF-α in a time-dependent manner, which showed significant reduction upon RIG-I ablation. " 05/01/2008 - "There was a statistically significant decline in IL-6 levels both before and during FMF attacks, following eradication therapy in patients who cleared the infection (p < 0.05). " 06/01/2000 - "Development of improved polymerase chain reaction-based clinical methods to detect intra-amniotic infection is necessary to better understand the relationship between elevated AF IL-6, intra-amniotic infection, and preterm delivery."
4.	Rheumatoid Arthritis 07/07/1998 - "Taken together, these results indicate that IL-6 may play a key role in the development of AIA at the inductive as well as the effector phase, and the blockade of IL-6 is possibly beneficial in the treatment of rheumatoid arthritis." 09/01/2013 - "Anti-IL-6R antibody, which has been effective in patients with rheumatoid arthritis, was administered to SCG/Kj mice to elucidate the role of IL-6 in the development of RPGN. " 06/01/2004 - "Overproduction of IL-6 plays pathologic roles in rheumatoid arthritis (RA), and the blockade of IL-6 may be therapeutically effective for the disease. " 05/01/2006 - "Blockade of interleukin-6 - the second generation of anticytokine therapy - may be a promising treatment for rheumatoid arthritis." 03/01/2015 - "IL-6 signal blockade ameliorates the enhanced osteoclastogenesis and the associated joint destruction in a novel FcγRIIB-deficient rheumatoid arthritis mouse model."
5.	Necrosis 02/01/2015 - "At the onset of acute Charcot foot, serum concentrations of tumour necrosis factor-α and interleukin-6 were elevated; however, there was a significant reduction in these markers at resolution and these markers may be useful in the assessment of disease activity." 01/01/2014 - "However, to date no studies have directly compared the utility of tumour necrosis factor (TNF) inhibition to that of interleukin-6. " 06/03/2013 - "The main aim of the study was to investigate serum levels of Interleukin-6 (IL-6) and Tumour Necrosis Factor-alpha (TNF-α) in melancholic and atypical depressive patients during acute exacerbations of illness, compared to healthy subjects. " 01/01/2013 - "CRP and IL-6 have shown a promising result in early detection of severity and pancreatic necrosis whereas APACHE-II and Ranson score in predicting AP related mortality in this study. " 01/01/2013 - "The aim of this study was to determine the salivary concentrations of tumour necrosis factor α (TNF-α) and interleukin 6 (IL-6) in patients with premalignant and malignant lesions. "

Related Drugs and Biologics

1.	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)
2.	Cytokines
3.	Interleukin-10 (Interleukin 10)
4.	Interleukin-8 (Interleukin 8)
5.	C-Reactive Protein
6.	tocilizumab
7.	Interleukin-1 (Interleukin 1)
8.	Messenger RNA (mRNA)
9.	Interleukin-1beta (Interleukin 1 beta)
10.	Insulin (Novolin)

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Aftercare (After-Treatment)
3.	Transplantation (Transplant Recipients)
4.	Immunotherapy
5.	Oral Administration